-
Clinical Trials & Development1 month agoSTAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better
-
Clinical Trials & Development1 month agoRoche drops muscle-sparing obesity antibody after flunked interim analysis
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.
-
Clinical Trials & Development1 month agoDaiichi Sankyo, MSD withdraw cancer drug application
The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which...
-
Clinical Trials & Development1 month agoMirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space...
-
Clinical Trials & Development1 month agoZenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria
PALO ALTO, Calif., Sept. 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics,...
-
Clinical Trials & Development1 month agoLow-Dose Radiation Shows Promise for Slowing Knee Osteoarthritis in Long-Term Trial
For millions of people living with knee osteoarthritis, treatment has long meant a choice between managing symptoms and waiting for the joint to wear out. A...
-
Clinical Trials & Development1 month agoRadiation Matches Heat in First Head-to-Head Trial for Colorectal Liver Metastases
For decades, patients whose colorectal cancer has spread to the liver in limited numbers have faced a frustrating gap in evidence: two widely used curative-intent treatments,...
-
Clinical Trials & Development1 month agoWnt drug gives MSD first eye disease win after EyeBio deal
MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
-
Clinical Trials & Development1 month agoNational Cancer Institute explainer for CSBA: Why and how to apply for SBIR
The SBIR and STTR federal seed funding programs—essential to many biotech start-ups—have been updated with important changes that provide new opportunities to applicants. These […] The...
-
Clinical Trials & Development1 month agoSTAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say
A recent court decision in Indonesia sends an important message to other countries to challenge the pharma industry's use of "patent evergreening," patient advocates say.
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
